Call for Abstract

International Conference on Neuro Oncology and Brain Tumor , will be organized around the theme “New Challenges and Latest Developments in Understanding Neuro-oncology and treating brain tumour ”

Neuro Oncology 2016 is comprised of 15 tracks and 159 sessions designed to offer comprehensive sessions that address current issues in Neuro Oncology 2016.

Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.

Register now for the conference by choosing an appropriate package suitable to you.

Neuro-oncology is the study of brain and spinal cord neoplasms, many of which are (at least eventually) very dangerous and life-threatening (astrocytoma, glioma, glioblastoma multiforme, ependymoma, pontine glioma, and brain stem tumors are among the many examples of these). Among the malignant brain cancers, gliomas of the brainstem and pons, glioblastoma multiforme, and high-grade (highly anaplastic) astrocytoma are among the worst. 


  • Track 1-1Central Nervous system Cancers
  • Track 1-2Central Nervous system Disorders
  • Track 1-3Neuro-oncology
  • Track 1-4Neurobiology
  • Track 1-5Advanced Biomarkers in Neuro-oncology
  • Track 1-6Neuro Degenrative disorders
  • Track 1-7Latest advances in Neuro-oncology
  • Track 1-8Immune Responses of the Nervous System
  • Track 1-9Brain Injury Rehabilitation
  • Track 1-10Cancer Metablolism
  • Track 1-11Stroke
  • Track 1-12Neurological Disorders
  • Track 1-13Alzheimers

Brain Cancer market is segmented on the basis of diagnosis and therapeutics. A brain cancer involves the growth of abnormal cells in the tissues of the brain. Primary brain cancer involves malignant tumor, Brain stem tumors, germ cell tumor, pituitary adenomas, Tumor development, DIPG, Cellular biology of brain cancer, primary CNS lymphomas, Pathophysiology and Risk factors of brain cancer and prognosis of brain tumors.

In 2011, 1,724 brain cancers were diagnosed in Australia. The risk of being diagnosed with a brain cancer by age 85 is 1 in 96 for men and 1 in 149 for women. In 2012, there were 1241 deaths in Australia caused by brain cancer.

Key market players which make a part in this field are Antisense Pharma, Novartis AG, AstraZeneca, Bristol-Myers Squibb, Pfizer Inc., Hoffmann-La Roche Ltd, Genentech and others

  • Track 2-1Tumor development
  • Track 2-2Brain Tumour Surgery
  • Track 2-3Brain Prognosis
  • Track 2-4Translational Research in Brain Tumors
  • Track 2-5Brain cancer awareness
  • Track 2-6Pathophysiology in Neuro-oncology
  • Track 2-7Primary CNS lymphomas
  • Track 2-8Pituitary adenomas
  • Track 2-9Germ cell tumor
  • Track 2-10Brain Cancer
  • Track 2-11Malignant tumour
  • Track 2-12Brain Toxicology

Glioblastoma multiforme (GBM) (named as glioblastoma) is a invasive glioma which is developed from star-shaped glial cells (i.e. astrocytes and oligodendrocytes) that support the health of the nerve cells within the brain. Almost 1 in 5 tumors in the brain are glioblastoma.

Glioblastoma multiforme occur most often in adults between the ages of 45 and 70 years. This tumor represents about 15.4% of all primary brain tumors and about 60-75% of all astrocytomas. They increase in frequency with age, and affect more men than women. Only three per cent of childhood brain tumors are glioblastoma

  • Track 3-1Glioblastoma
  • Track 3-2Advances in treatment of Glioblastoma
  • Track 3-3High–Grade & Low Grade Gliomas
  • Track 3-4Diagnosis and Treatment
  • Track 3-5Pathology and Molecular Genetics
  • Track 3-6Whole-genome analysis of gliomas 
  • Track 3-7Causes and Symptoms
  • Track 3-8Diffuse Intrinsic Pontine Glioma(DIPG)
  • Track 3-9Glioblastoma in Children
  • Track 3-10Olingodendrogliomas in adults
  • Track 3-11Role of Gliomas in Neuro-oncology

When cancer develops elsewhere in the body and spreads (metastasizes) to the brain, which is called as secondary brain tumor, or metastatic brain cancer. Brain metastases (secondary brain tumors) occur in approximately 15% of cancer patients as a result of haematogenous dissemination of cancer, and the incidence may be rising because of better control of systemic disease. 

The overall annual incidence of primary brain tumors in the United States is 9.5 cases per 100,000 population. Over 60% of primary brain tumors are gliomas, and at least two-thirds of these are clinically aggressive and high grade. Brain tumors represent 20% of all childhood malignancies and are the number two cause of cancer death in children after leukaemia

  • Track 4-1Brain Metastases
  • Track 4-2Causes and Symptoms of metastatic tumors
  • Track 4-3Malignant melanoma
  • Track 4-4Intracranial Metastasis
  • Track 4-5Skull Metastasis
  • Track 4-6Spinal Metastasis
  • Track 4-7Targeted Therapy in Neuro-oncology
  • Track 4-8Current approaches of metastatic tumors
  • Track 4-9Metastatic Cancer

Angiogenesis plays a critical role in the growth and spread of cancer, it also plays a major role in the transition of tumors from a benign state to a malignant (cancerous), leading to the use of angiogenesis inhibitors in the treatment of cancer.

Angiogenesis is a vital process that facilitates tumor growth and survival. Angiogenesis is a well-controlled process that is regulated by angiogenic, growth, and survival factors that are secreted by the malignant cells as well as other cells within the tumor microenvironment.

  • Track 5-1Angiogenesis in Neuro Oncology
  • Track 5-2Tumor Angiogenesis
  • Track 5-3Cell interactions
  • Track 5-4Angiogenesis inhibitors
  • Track 5-5Stem Cells
  • Track 5-6Anti-angiogenic Therapies
  • Track 5-7Recent developments
  • Track 5-8Brain Diagnosis
  • Track 5-9Brain Tumour

Radiation Oncology encompasses all aspects of research that impacts on the treatment of cancer using radiation. It discloses findings in molecular and cellular radiation oncology, radiation technology, radiation physics, and clinical oncology.

Radiation Oncology is made up of three unique medical specialties that focus on the treatment of cancer patients with radiotherapy treatment (also known as radiation therapy); namely Radiation Oncologists, Radiation Therapists and Radiation Physicists

  • Track 6-1Radiosensitizers
  • Track 6-2Neuroradiology
  • Track 6-3Recent developments
  • Track 6-4Quality Measures of  Radiotherapy
  • Track 6-5Intensity modulated radiation therapy(IMRT)
  • Track 6-6Clinical Radiation Oncology
  • Track 6-7Radiation physics
  • Track 6-8Palliative radiotherapy in Neuro-oncology
  • Track 6-9Radiation Oncology
  • Track 6-10Molecular Radiation Oncology
  • Track 6-11Cellular Radiation Oncology
  • Track 6-12Advanced MRI in Neuro-Oncology

The primary method which is used in the initial diagnosis, monitoring of response, and process of progression in Neuro-oncology is neuroimaging techniques. Neuro imaging has enabled great progress in the diagnosis of brain cancer, as well as finding useful application in medical research and practice.

There are a number of accepted, safe imaging techniques in use today in research facilities and hospitals throughout the world which includes FMRI, CT scan, PET, EEG, MEG, NIRS. This session includes latest technologies and developments of Structural and functional imaging, Biomarker Discovery, Radioactive compounds in Neuroimaging, Computed tomography, Diffuse optical imaging, Magnetic resonance imaging, Positron emission tomography.

  • Track 7-1Structural and functional imaging
  • Track 7-2Brain Imaging
  • Track 7-3Advanced Imaging of adult brain tumors
  • Track 7-4Advances in Diagnostic test on Neuro-oncology
  • Track 7-5Diagnosis of Neuro-oncology
  • Track 7-6Magnetic resonance imaging
  • Track 7-7Radioactive compounds in NeuroImaging
  • Track 7-8Neuro imaging
  • Track 7-9Positron emission tomography
  • Track 7-10Diffuse optical imaging
  • Track 7-11Computed tomography
  • Track 7-12Biomarker Discovery
  • Track 7-13Neurosurgery

About one-third of patients are being treated for cancer pain, which leads to many different forms. It may be short-lived or long-lasting, mild or severe, or effect on few organs, bones or organ system. Since each patient’s pain is unique, it is determined that cancer pain management treatment plans must be adapt to address individual needs.


  • Track 8-1Types of pain in Neuro-oncology
  • Track 8-2Pain-relieving therapies
  • Track 8-3Non-Drug Pain Treatment
  • Track 8-4Treating Cancer Pain
  • Track 8-5Causes of Cancer Pain
  • Track 8-6Pain Management in Neuro-oncology
  • Track 8-7Referred pain
  • Track 8-8Phantom pain
  • Track 8-9Soft tissue pain
  • Track 8-10Bone pain
  • Track 8-11Nerve pain
  • Track 8-12Acute and chronic pain
  • Track 8-13Advanced Technologies

Pediatric Neuro-oncology is a fast developing field. Brain tumors are the cause of cancer-related deaths among children. Brain disorders are the most common solid malignancy in children.  Their bodies and brains are still developing. Their tumors are different.  The common childhood brain cancers are not the same as the most common adult brain cancers. Though they are rare, brain tumors are very common form of solid tumors among children under the age of 15 and represent about 20% of all childhood cancers. 

Childhood tumors frequently appear in different locations and behave differently than brain tumors appearing in adults.  Treatment options are different and can be strongly influenced by the age of the child.  Children suffering from brain cancer may also have a much better prognosis than adults with a similar condition. The common types of brain tumors in children are Neurofibromatosis, Primitive Neuroectodermal tumor, Leukaemia, Neuroblastoma, Medulloblastoma, Ependymoma and Astrocytoma.

  • Track 9-1Cancer Stem Cells
  • Track 9-2Pediatric Neuro-oncology
  • Track 9-3Astrocytoma
  • Track 9-4Medulloblastoma
  • Track 9-5Translational Therapeutics in Neuro-oncology
  • Track 9-6Epigenetics in Pediatric Cancers
  • Track 9-7Ependymoma
  • Track 9-8Neuroblastoma
  • Track 9-9Leukemia
  • Track 9-10Neurofibromatosis
  • Track 9-11Neurocutaneous Disorders
  • Track 9-12Pediatric Brain Tumor Models
  • Track 9-13Implications and challenges
  • Track 9-14Proton Radiotherapy for Pediatric Brain Tumors

Neurosurgery is a complex surgical procedure that involves treatment, diagnosis, and rehabilitation of disorders affecting any region of the nervous system.

Some of the most common Neurosurgeries are skull base surgery, Image Guided Surgery, Laser Surgery ,  spinal Neurosurgery and  Neurosurgical treatment. The Global Neurosurgery market is expected to grow 11.71% over the period of 2014-2019.

Neurosurgery session includes Image Guided Surgery, Laser Surgery, Surgical management for brain tumors, spinal neurosurgery, skull base surgery, Neurosurgical treatment, Geriatric Neurosurgery, latest innovations and techniques

  • Track 10-1Neurosurgery
  • Track 10-2Clinical Neurosurgery
  • Track 10-3latest innovations and techniques
  • Track 10-4Geriatric Neurosurgery
  • Track 10-5Neurosurgical treatment in Neuro-oncology
  • Track 10-6Paediatric Neurosurgery
  • Track 10-7Stereotactic and Functional Neurosurgery
  • Track 10-8CNS Neurosurgery
  • Track 10-9skull base surgery
  • Track 10-10Surgical mangement for brain tumors
  • Track 10-11Laser Surgery
  • Track 10-12Image Guided Surgery
  • Track 10-13Neurophysiology
  • Track 11-1Spinal cord Injury
  • Track 11-2Spine tumors
  • Track 11-3Spine surgery
  • Track 11-4spine disorders
  • Track 11-5Spine Therapy
  • Track 11-6Recent research developments

The work of the neuropathologist consists largely of examining biopsy tissue from the brain and spinal cord to aid in diagnosis of disease. The biopsy is usually requested after a mass is detected by radiologic imaging. As for autopsies, the principal work of the neuropathologist is to help in the post-mortem diagnosis of various forms of dementia and other conditions that affect the central nervous system.

Neuropathology is the study of disease of nervous system tissue, usually in the form of either small surgical biopsies or whole autopsies. Neuropathology is a subspecialty of anatomic pathology, neurology, and neurosurgery.

  • Track 12-1Neuropathology
  • Track 12-2Neuropathology of Aging
  • Track 12-3Neuropathology of Brain Tumor
  • Track 12-4Neuropathology of Neurodegenerative disorders
  • Track 12-5Neuropathology of Neuro-Oncology
  • Track 12-6Clinical Neuropathology
  • Track 12-7Functional Neuroanatomy
  • Track 12-8Treament and advancement in neuropathology

Brain cancer market is segmented on the basis of diagnosis and therapeutics.  Major research is going on targeted Therapies for Brain Cancer. On the basis of treatment the market is segmented into surgeries, radiation therapy, immunotherapy, chemotherapy, and targeted therapy. Therapeutic approaches include Chemotherapy Intensity modulated radiation therapy, palliative care, vaccine therapy, surgical delivery, Molecular pathology for clinician and challenges in therapy.


  • Track 13-1Therapeutic approaches in Neuro-oncology
  • Track 13-2Neuropharmacology
  • Track 13-3Latest drug developments in Neuro oncology
  • Track 13-4Challenges in radiotherapy
  • Track 13-5Palliative care of Neuro-oncology
  • Track 13-6Surgical Delivery
  • Track 13-7Molecular Pathology in Neuro-oncology
  • Track 13-8Vaccine therapy
  • Track 13-9Chemotherapy
  • Track 13-10Immunotherapy

Tumour heterogeneity relate differences between tumours of the same type in different patients, and also difference between cancer cells within a tumour cells can show distinct  including cellular morphology, motility, gene expression, proliferation, metabolism, and metastatic potential. This process occurs both between tumours which is called as inter-tumour heterogeneity and within tumours called as intra-tumour heterogeneity. It plays a major role in brain Cancer.

Genetic and epigenetic differences between cancer cells within a tumour might explain why some tumour cells remain present in the patient even after cancer treatment has finished. Most current efforts are focused on understanding heterotypic interactions between tumor cells and surrounding normal cells, which is known about the interactions between and among heterogeneous tumor cells within a neoplasm. Tumor Heterogeneity covers Inter- intra tumour heterogeneity, Cancer Stem Cells, Brain Tumor Microenvironment, Experimental- Sequencing, Genetic Heterogeneity and Implications and challenges

  • Track 14-1Tumour Heterogeneity
  • Track 14-2Inter- intra tumour heterogeneity
  • Track 14-3Brain Tumor Microenvironment
  • Track 14-4Experimental: Sequencing
  • Track 14-5Cancer Stem Cells
  • Track 14-6Genetic Heterogeneity in Neuro-oncology
  • Track 14-7Implications and challenges
  • Track 14-8Neuroimmunology
  • Track 14-9Cancer cell biology

Brain Cancer clinical trials are research studies that test new and better ways to prevent, diagnose and treat Brain cancer. A world-first human trial has been set to begin in Brisbane and Melbourne has the potential to be one of the biggest breakthroughs in the treatment of brain cancer, researchers say. According to the Cure Brain Cancer Foundation worth of $500,000 provided to the study over the next three years.

The Centre for Neuro-Oncology offers the latest advances in care for adult patients with brain tumors or spinal cord tumors, as well as for neurologic complications of brain cancer and its treatments. The Australian Government is supporting Australia’s capacity to develop industry-independent cancer clinical trials.

  • Track 15-1Clinical trials in Neuro-oncology
  • Track 15-2Antitumor Activity
  • Track 15-3Clinical trial design in Neuroscience
  • Track 15-4Clinical Oncology
  • Track 15-5Drug compounds targeting Tumor metabolism
  • Track 15-6Anticancer drug discovery and development
  • Track 15-7Anticancer drug discovery and development